Pullulan Hydrogel Delivery of FAK Inhibitor for Scar Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for preventing and treating scarring are ineffective due to a lack of understanding of the underlying pathophysiology, particularly for large areas of wounds resulting from extensive burns, traumatic injuries, or excisional skin surgeries, where off-loading mechanical strain is not applicable.
Innovation Solution
A composition comprising a porous scaffold, such as a pullulan-collagen hydrogel, with a focal adhesion kinase (FAK) inhibitor like VS-6062, designed for controlled release to reduce scarring and promote tissue healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If off-loading mechanical strain using stress-shielding devices is applied, then scar development is inhibited in large animals and humans, but this approach is not applicable to large areas of wounds resulting from extensive burns, traumatic blast injuries, or excisional skin surgeries
Solution Approach 1:
The patent introduces a biomaterial-based dressing as an intermediary carrier that delivers FAK inhibitor to the wound site. This mediator enables targeted drug delivery to large area wounds where mechanical strain off-loading is not applicable, resolving the contradiction between scar inhibition and adaptability to different wound types.
Solution Approach 2:
The patent changes the delivery mechanism from mechanical strain off-loading to pharmacological inhibition via controlled release. By transforming the approach from physical to chemical/biological intervention, the treatment becomes applicable to large area wounds while maintaining scar reduction efficacy.
2Object-affected harmful factors
If FAK inhibitor is delivered via local subcutaneous injection, then local inflammatory responses are abrogated and scar development is decreased, but this method is not suitable for large area wounds
Solution Approach 1:
The patent employs a porous biomaterial dressing that can be applied to large wound surfaces. The porous structure enables controlled release of FAK inhibitor across extensive areas, simultaneously addressing the need for broad coverage and sustained anti-inflammatory and anti-scar effects.
Solution Approach 2:
The biomaterial dressing serves multiple functions: it acts as a wound covering, a drug delivery system, and a controlled release mechanism. This multi-functionality enables treatment of large area wounds while maintaining the benefits of localized FAK inhibition.
3Manufacturing precision
If a porous scaffold with FAK inhibitor is used for controlled release, then targeted drug delivery is achieved, but the device complexity increases
Solution Approach 1:
The patent controls the release rate by adjusting material parameters of the porous scaffold such as pore size, porosity, and degradation characteristics. By optimizing these parameters, controlled release is achieved without requiring complex mechanical or electronic control systems, thus managing device complexity.
Solution Approach 2:
The porous scaffold utilizes its own structural properties (porosity, surface area, degradation) to enable controlled drug release. The scaffold serves itself by using its inherent characteristics to regulate FAK inhibitor delivery, eliminating the need for external control mechanisms and reducing overall device complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively accelerates wound healing, reduces scar formation, and improves mechanical properties of healed skin by inhibiting FAK activity, demonstrating potential for targeted and controlled drug delivery in large and deep dermal wounds.
Implementation Method 1
a porous scaffold, such as a pullulan-collagen hydrogel, with a focal adhesion kinase (FAK) inhibitor like VS-6062, designed for controlled release
Implementation Method 2
the porous scaffold includes a pullulan-collagen hydrogel
Data Source
AI summary
The formation of scars at a wound site is reduced by contacting the wound site with an effective dose of an inhibitor of focal adhesion kinase (FAK) formulated in a pullulan hydrogel The release profile of the FAK inhibitor can be adjusted according to the nature of the wound, e.g., excisional wounds, burn wounds, etc.